Contributions of the international plant science community to the fight against infectious diseases in humans—part 2: Affordable drugs in edible plants for endemic and re‐emerging diseases

Wenshu He,Can Baysal,Maria Lobato Gómez,Xin Huang,Derry Alvarez,Changfu Zhu,Victoria Armario‐Najera,Aamaya Blanco Perera,Pedro Cerda Bennaser,Andrea Saba‐Mayoral,Guillermo Sobrino‐Mengual,Ashwin Vargheese,Rita Abranches,Isabel Alexandra Abreu,Shanmugaraj Balamurugan,Ralph Bock,Johannes F. Buyel,Nicolau B. Cunha,Henry Daniell,Roland Faller,André Folgado,Iyappan Gowtham,Suvi T. Häkkinen,Shashi Kumar,Ramalingam Sathish Kumar,Cristiano Lacorte,George P. Lomonossoff,Ines M. Luís,Julian K.‐C.,Karen A. McDonald,Andre Murad,Somen Nandi,Barry O’Keef,Subramanian Parthiban,Mathew J. Paul,Daniel Ponndorf,Elibio Rech,Julio C.M. Rodrigues,Stephanie Ruf,Stefan Schillberg,Jennifer Schwestka,Priya S. Shah,Rahul Singh,Eva Stoger,Richard M. Twyman,Inchakalody P. Varghese,Giovanni R. Vianna,Gina Webster,Ruud H. P. Wilbers,Paul Christou,Kirsi‐Marja Oksman‐Caldentey,Teresa Capell,Julian K.‐C. Ma

DOI: https://doi.org/10.1111/pbi.13658

IF: 13.8

2021-07-19

Plant Biotechnology Journal

Abstract:<p>The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re-emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of <i>Artemisia annua</i> against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical-grade protein drugs in leaves to treat infectious diseases, and the long-term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure, and that eliminate the need for expensive purification steps and sterile delivery by injection.</p>

biotechnology & applied microbiology,plant sciences